Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Paul Le Baccon-Sollier, Yohan Malki, Morgane Maye, Lamiaa M. A. Ali, Laure Lichon, Pierre Cuq, Laure-Anaïs Vincent & Nicolas Masurier. (2020) Imidazopyridine-fused [1,3]diazepinones: modulations of positions 2 to 4 and their impacts on the anti-melanoma activity. Journal of Enzyme Inhibition and Medicinal Chemistry 35:1, pages 935-949.
Read now
Read now
Articles from other publishers (29)
Tarak Chouari, Francesca Soraya La Costa, Nabeel Merali, Maria-Danae Jessel, Shivan Sivakumar, Nicola Annels & Adam E. Frampton. (2023) Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma. Cancers 15:17, pages 4265.
Crossref
Crossref
Jiayu Zhang, Ting YangMei HanXiaoxuan WangWeiming YangNing GuoYong RenWei CuiShangxiao LiYongshan Zhao, Xin Zhai, Lina JiaJingyu Yang, Chunfu WuLihui Wang. (2023)
Gain-of-function mutations in the catalytic domain of
DOT1L
promote lung cancer malignant phenotypes via the MAPK/ERK signaling pathway
. Science Advances 9:22.
Crossref
Crossref
Abdelhabib Semlali, Ikram Ajala, Sarra Beji, Mohammed Mousa Al-Zharani & Mahmoud Rouabhia. (2023) Synergistic Effect of Anethole and Platinum Drug Cisplatin against Oral Cancer Cell Growth and Migration by Inhibiting MAPKase, Beta-Catenin, and NF-κB Pathways. Pharmaceuticals 16:5, pages 700.
Crossref
Crossref
Katarzyna Szklener, Marek Mazurek, Małgorzata Wieteska, Monika Wacławska, Mateusz Bilski & Sławomir Mańdziuk. (2022) New Directions in the Therapy of Glioblastoma. Cancers 14:21, pages 5377.
Crossref
Crossref
Fatih M. Uckun & Sanjive Qazi. (2022) ERBB1/EGFR and JAK3 Tyrosine Kinases as Potential Therapeutic Targets in High-Risk Multiple Myeloma. Onco 2:4, pages 282-304.
Crossref
Crossref
Izabela Rumienczyk, Maria Kulecka, Małgorzata Statkiewicz, Jerzy Ostrowski & Michal Mikula. (2022) Oncology Drug Repurposing for Sepsis Treatment. Biomedicines 10:4, pages 921.
Crossref
Crossref
Alexandra Landras, Coralie Reger de Moura, Bruno O. Villoutreix, Maxime Battistella, Aurélie Sadoux, Nicolas Dumaz, Suzanne Menashi, Juan Fernández-Recio, Céleste Lebbé & Samia Mourah. (2022) Novel treatment strategy for NRAS-mutated melanoma through a selective inhibitor of CD147/VEGFR-2 interaction. Oncogene 41:15, pages 2254-2264.
Crossref
Crossref
Samanta Oliveira da Silva & Ellen Mayara Corrêa. 2022. The Golden Guide to Oncologic Pharmacy. The Golden Guide to Oncologic Pharmacy
121
176
.
Seong-Ah Shin, Jun Seob Lee, Byeong Jun Joo, Gyoungah Ryu, Minjoo Han, Huiji Kim, Jangeun An, Man Hyung Koo, Ui Joung Youn, Jun Hyuck Lee, Hyun Ho Park & Chang Sup Lee. (2021) Anti-cancer effects of lucidadiol against malignant melanoma cells. Applied Biological Chemistry 64:1.
Crossref
Crossref
Anisha S. Jain, Ashwini Prasad, Sushma Pradeep, Chandan Dharmashekar, Raghu Ram Achar, Ekaterina Silina, Victor Stupin, Raghavendra G. Amachawadi, Shashanka K. Prasad, R Pruthvish, Asad Syed, Chandan Shivamallu & Shiva Prasad Kollur. (2021) Everything Old Is New Again: Drug Repurposing Approach for Non-Small Cell Lung Cancer Targeting MAPK Signaling Pathway. Frontiers in Oncology 11.
Crossref
Crossref
XuSha Zhou, Jing Zhao, Jian V. Zhang, Yinglin Wu, Lei Wang, Xiaoqing Chen, Dongmei Ji & Grace Guoying Zhou. (2021) Enhancing Therapeutic Efficacy of Oncolytic Herpes Simplex Virus with MEK Inhibitor Trametinib in Some BRAF or KRAS-Mutated Colorectal or Lung Carcinoma Models. Viruses 13:9, pages 1758.
Crossref
Crossref
Akhmad Madaminov, Akbar Khasanov, Shuhrat Khatamov, Otabek Abdurakhmonov, Anvar Amonov, Zohir Shukurov, Murod Khudayorov, Rahim Bekmirzaev & Latif Nishonboev. (2021) Cancer - dysregulation of the cell cycle and transduction of cascade signals. Romanian Journal of Rhinology 11:43, pages 90-100.
Crossref
Crossref
Holly Coleman, Muhammad Raisul Abedin, Kaitlyne Powers & Sutapa Barua. (2021) The Role of Intrinsic Signaling Pathways in Cell Proliferation. Nano LIFE 11:01, pages 2030003.
Crossref
Crossref
E. Kun, Y.T.M. Tsang, C.W. Ng, D.M. Gershenson & K.K. Wong. (2021) MEK inhibitor resistance mechanisms and recent developments in combination trials. Cancer Treatment Reviews 92, pages 102137.
Crossref
Crossref
Nataša Anastasov, Elisabeth Hirmer, Marbod Klenner, Jessica Ott, Natalie Falkenberg, Xuanwen Bao, Lisa Mutschelknaus, Simone Moertl, Stephanie Combs, Michael J. Atkinson & Thomas Schmid. (2020) MEK1 Inhibitor Combined with Irradiation Reduces Migration of Breast Cancer Cells Including miR-221 and ZEB1 EMT Marker Expression. Cancers 12:12, pages 3760.
Crossref
Crossref
Ning Tang, Dan Lyu, Jian-Fang Chang, Zhi-Tao Liu, Yan Zhang & Hai-Ping Liu. (2020) Enhanced expression of microtubule-associated protein 7 functioned as a contributor to cervical cancer cell migration and is predictive of adverse prognosis. Cancer Cell International 20:1.
Crossref
Crossref
Eucharist H. S. Kun, Yvonne T. M. Tsang, Sophia Lin, Sophia Pan, Tejas Medapalli, Anais Malpica, JoAnne S. Richards, David M. Gershenson & Kwong-Kwok Wong. (2020) Differences in gynecologic tumor development in Amhr2-Cre mice with KRASG12D or KRASG12V mutations. Scientific Reports 10:1.
Crossref
Crossref
Sabah Akhtar, Tayyiba A. Ali, Ammara Faiyaz, Omar S. Khan, Syed Shadab Raza, Michal Kulinski, Halima El Omri, Ajaz A. Bhat & Shahab Uddin. (2020) Cytokine-Mediated Dysregulation of Signaling Pathways in the Pathogenesis of Multiple Myeloma. International Journal of Molecular Sciences 21:14, pages 5002.
Crossref
Crossref
Louis Buscail, Barbara Bournet & Pierre Cordelier. (2020) Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nature Reviews Gastroenterology & Hepatology 17:3, pages 153-168.
Crossref
Crossref
Yanan Li, Qingrong Dong, Ting Mei, Meichen Zheng, Ramasamy Raj Kumar, Bin Yu, Chunsheng Wu, Hui Zhang & Feifei An. (2020) Nanosized Modification Strategies for Improving the Antitumor Efficacy of MEK Inhibitors. Current Drug Targets 21:3, pages 228-251.
Crossref
Crossref
Shannon Lee, Jens Rauch & Walter Kolch. (2020) Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity. International Journal of Molecular Sciences 21:3, pages 1102.
Crossref
Crossref
Mengyi Zhang, Baocheng Wang, Qing-Yun Chong, Vijay Pandey, Zhirong Guo, Ru-Mei Chen, Lingzhi Wang, Yanxin Wang, Lan Ma, Alan P. Kumar, Tao Zhu, Zheng-Sheng Wu, Zhinan Yin, Basappa, Boon-Cher Goh & Peter E. Lobie. (2019) A novel small-molecule inhibitor of trefoil factor 3 (TFF3) potentiates MEK1/2 inhibition in lung adenocarcinoma. Oncogenesis 8:11.
Crossref
Crossref
Vipin Shankar Chelakkot, Jayoti Som, Ema Yoshioka, Chantel P. Rice, Suzette G. Rutihinda & Kensuke Hirasawa. (2019) Systemic MEK inhibition enhances the efficacy of 5-aminolevulinic acid-photodynamic therapy. British Journal of Cancer 121:9, pages 758-767.
Crossref
Crossref
Dandan Wang, Weijie Zhou, Jingyu Chen & Wei Wei. (2019) Upstream regulators of phosphoinositide 3‐kinase and their role in diseases. Journal of Cellular Physiology 234:9, pages 14460-14472.
Crossref
Crossref
Bin Zhang, Mei Meng, Shufen Xiang, Zhifei Cao, Xingdong Xu, Zhe Zhao, Tong Zhang, Bowen Chen, Ping Yang, Ye Li & Quansheng Zhou. (2019) Selective activation of tumor-suppressive MAPKP signaling pathway by triptonide effectively inhibits pancreatic cancer cell tumorigenicity and tumor growth. Biochemical Pharmacology 166, pages 70-81.
Crossref
Crossref
Paola Savoia, Paolo Fava, Filippo Casoni & Ottavio Cremona. (2019) Targeting the ERK Signaling Pathway in Melanoma. International Journal of Molecular Sciences 20:6, pages 1483.
Crossref
Crossref
Yi Zhi, Xiaojun Wu, Wenhao Shen, Yongquan Wang, Xiaozhou Zhou, Peng He, Jinhong Pan, Zhiwen Chen, Weibing Li & Zhansong Zhou. (2018) Synthesis and pharmacological evaluation of novel epidermal growth factor receptor inhibitors against prostate tumor cells. Oncology Letters.
Crossref
Crossref
Michela Illiano, Luigi Sapio, Alessia Salzillo, Lucia Capasso, Ilaria Caiafa, Emilio Chiosi, Annamaria Spina & Silvio Naviglio. (2018) Forskolin improves sensitivity to doxorubicin of triple negative breast cancer cells via Protein Kinase A-mediated ERK1/2 inhibition. Biochemical Pharmacology 152, pages 104-113.
Crossref
Crossref
Ying Cheng & Hongqi Tian. (2017) Current Development Status of MEK Inhibitors. Molecules 22:10, pages 1551.
Crossref
Crossref